In one paragraphArticle in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Joseph C F NgResearch Department of Structural and Molecular Biology, Division of Biosciences, University College London, London, UK.ORCID 0000-0002-3617-5211 Alicia ChenowethSt. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK.ORCID 0000-0002-2736-9268 Maria Laura De SciscioResearch Department of Structural and Molecular Biology, Division of Biosciences, University College London, London, UK.ORCID 0000-0001-5523-0987 Melanie GranditsSt. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK.ORCID 0000-0001-8143-8298 Anthony CheungSt. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK.ORCID 0000-0002-2988-2786 Tooki ChuResearch Department of Structural and Molecular Biology, Division of Biosciences, University College London, London, UK.ORCID 0009-0003-3344-0336 Alexandra McCrawSt. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK.ORCID 0009-0008-2412-4389 Jitesh ChauhanSt. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK.ORCID 0000-0002-3968-9234 Yi LiuSt. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK.
Dongjun GuoResearch Department of Structural and Molecular Biology, Division of Biosciences, University College London, London, UK.ORCID 0009-0004-1037-9269 Semil PatelSt. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK.
Alice KosmiderRandall Centre for Cell & Molecular Biophysics, School of Basic & Medical Biosciences, King's College London, London, UK.
Daniela IancuResearch Department of Structural and Molecular Biology, Division of Biosciences, University College London, London, UK.
Sophia N KaragiannisSt. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK.ORCID 0000-0002-4100-7810 Franca FraternaliResearch Department of Structural and Molecular Biology, Division of Biosciences, University College London, London, UK.ORCID 0000-0002-3143-6574 Funding
Biotechnology and Biological Sciences Research Council BB/T002212/1Breast Cancer Now 147; KCL-BCN-Q3China Scholarship Council 202008440414CRUK City of London Centre Award C7893/A29290Worldwide Cancer Research 24-0087
6 · The paper itselfAbstract
Artificial intelligence and machine learning models have been developed to engineer antibodies for specific recognition of antigens. These approaches, however, often focus on the antibody complementarity-determining region (CDR) whilst ignoring the immunoglobulin framework (FW), which provides structural rigidity and support for the flexible CDR loops. Here we present an integrated computational-experimental workflow, combining static structure analyses, molecular dynamics simulations and
Indexed as
Complementarity Determining RegionsMutationProtein EngineeringTrastuzumabErb-b2 Receptor Tyrosine KinasesHumansMolecular Dynamics SimulationProtein StabilityComplementarity Determining RegionsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabAntibody effector functionsAntibody engineeringAntibody frameworkAntibody language modelsAntibody stabilityArtificial intelligence
Identifiers
PMID40653772
PMCPMC12269682
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390